In summary we identified a novel role of TR4 that may function via altering the TR4/lincRNA-p21/HIF-1α/VEGF-A signaling to modulate the DTX resistance in PCa, and targeting this newly identified signaling with Bex, an FDA-approved drug, may lead to increase DTX chemo-sensitivity to better suppress the mCRPC progression. The gene discussed is NR2C2; the disease is posterior cortical atrophy.